Hexarelin Dosage Guide

Evidence-based protocols for the most potent growth hormone releasing peptide — CD36 cardioprotection, desensitization management, stacking with CJC-1295, cycling, and safety.

Compiled by PeptideWiki Editorial Team·Last reviewed February 24, 2026

A leading innovator in research chemicals.

All products HPLC tested

|Exclusive Offer

Coupon

10%

Off

Use our affiliate link and code PEPTIDEWIKI at checkout to unlock your 10% discount, every time you use the code.

Shop Now

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

Research Peptides

Hexarelin

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

What Is Hexarelin?

Hexarelin (Examorelin) is a synthetic hexapeptide growth hormone releasing peptide (GHRP) and the most potent member of the GHRP family. It produces the largest growth hormone pulse of any GHRP — significantly greater than GHRP-2, GHRP-6, or Ipamorelin on a microgram-per-microgram basis. Its amino acid sequence is His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2.

What makes Hexarelin unique among GHRPs is its dual mechanism of action. Like all GHRPs, it activates the GHS-R1a (ghrelin) receptor on pituitary somatotrophs to trigger GH release. But Hexarelin also binds to CD36 scavenger receptors on cardiac tissue — a mechanism completely independent of GH. This CD36 activation reduces cardiac fibrosis, protects against ischemia-reperfusion injury, and improves left ventricular ejection fraction (LVEF) in animal models. No other GHRP has demonstrated this cardioprotective effect.

The trade-off for Hexarelin's potency is the highest desensitization risk of any GHRP. Continuous daily use beyond 4–8 weeks progressively blunts the GH response as GHS-R1a receptors downregulate. This makes cycling mandatory — not optional. This guide covers dosing protocols, desensitization management, stacking with CJC-1295, CD36 cardioprotection, and safety considerations.

Use our Peptide Dosage to calculate your exact dose based on vial size and concentration.

Dosing information in this guide is derived from clinical studies and community protocols — not from approved pharmaceutical labeling.

Key Characteristics:

Most potent GHRP — produces the largest GH pulse of any growth hormone releasing peptide in head-to-head comparisons
Hexapeptide — 6 amino acids: His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2
Dual mechanism — GHS-R1a receptor activation (GH release) + CD36 scavenger receptor binding (cardioprotection) — unique among GHRPs
CD36 cardioprotection — reduces cardiac fibrosis, protects against ischemia-reperfusion injury, improves LVEF in animal models
Highest desensitization risk — mandatory cycling (4–8 weeks on, equal time off) required to maintain GH response
Half-life ~70 minutes — GH peak occurs 15–30 minutes post-injection; space multiple daily injections at least 3 hours apart

For a complete overview of its mechanism and research, see our full Hexarelin profile. New to peptides? Start with the Beginner's Guide to Peptides.

How Hexarelin Dosage Is Determined

Hexarelin dosing is better supported by human clinical data than most research peptides. Multiple studies by Arvat, Ghigo, and colleagues have established dose-response relationships in healthy volunteers. The commonly used 100–200 mcg range is derived directly from these clinical findings, supplemented by community experience.

Clinical Dose-Response Studies

Arvat et al. demonstrated a clear dose-response relationship for Hexarelin in healthy adults, with GH output increasing from 1 mcg/kg through 2 mcg/kg. At doses above approximately 2 mcg/kg (roughly 150–200 mcg for an average adult), GH release plateaus — higher doses do not produce proportionally greater GH but do increase cortisol and prolactin elevation. This ceiling effect is the basis for the 200 mcg maximum per injection.

Desensitization Studies

Broglio et al. and Ghigo et al. documented progressive attenuation of the GH response with continuous Hexarelin administration. After 4–8 weeks of daily dosing, the GH pulse was significantly reduced compared to baseline — confirming the need for cycling. Receptor downregulation appears dose-dependent: higher daily doses and more frequent injections accelerate desensitization.

CD36 Research

Muccioli et al. identified Hexarelin's binding to CD36 scavenger receptors on cardiac tissue — an effect independent of GH release and unique to Hexarelin among GHRPs. This research demonstrated cardioprotective effects including reduced cardiac fibrosis and protection against ischemia-reperfusion injury. The CD36 effect occurs at standard dosing ranges and does not require higher doses.

Strength of evidence: Moderate. Hexarelin has more human clinical data than most GHRPs, including controlled dose-response and desensitization studies. CD36 cardioprotection is well-characterized in animal models. However, long-term safety data and large-scale clinical trials are lacking. Dosing protocols are based on clinical pharmacology studies and community experience.

Standard Hexarelin Dosage Ranges

Hexarelin is administered by subcutaneous injection on an empty stomach. The dose-response ceiling at 200 mcg per injection is well-established — exceeding this does not increase GH output but does increase side effects. All injections should be performed fasted (at least 2 hours after eating, 30–45 minutes before eating).

Dosage by Experience Level

Level	Dose per Injection	Frequency	Daily Total	Notes
Beginner	100 mcg	1–2x daily	100–200 mcg	Assess tolerance and side effects; ideal starting point
Intermediate	200 mcg	2x daily	400 mcg	Standard protocol for most users; dose-response ceiling per injection
Advanced	200 mcg	3x daily	600 mcg	Maximum practical dosing; higher desensitization risk at this frequency

Injection Timing

Always fasted: Inject at least 2 hours after eating and 30–45 minutes before eating
Space injections 3+ hours apart: The pituitary needs time to replenish GH stores between pulses
Optimal timing (2x daily): Morning upon waking (fasted) + before bed (fasted 2–3 hours)
Optimal timing (3x daily): Morning + mid-afternoon + before bed — all fasted windows

200 mcg ceiling: Do not exceed 200 mcg per injection. Research consistently shows that the GH response plateaus at this dose. Higher amounts simply increase cortisol and prolactin elevation without additional GH benefit. If you want more GH output, add a GHRH analog like CJC-1295 — do not increase the Hexarelin dose above 200 mcg.

GHRP Potency Comparison

Not all GHRPs are equal. They share the same GHS-R1a receptor but differ significantly in GH potency, side effect profiles, and desensitization risk. This table compares the four most commonly used GHRPs across key parameters.

Parameter	Hexarelin	GHRP-2	GHRP-6	Ipamorelin
GH Release Potency	Highest	High	Moderate	Moderate
Cortisol Elevation	Significant	Moderate	Moderate	Minimal
Prolactin Elevation	Significant	Moderate	Moderate	Minimal
Appetite Increase	Moderate	Moderate	Strongest	Minimal
Desensitization Risk	Highest	Moderate	Moderate	Low
Cardioprotection (CD36)	Yes (unique)	No	No	No
Cycling Required?	Mandatory	Recommended	Recommended	Optional
Best For	Short intense cycles, cardio	Balanced GH + tolerability	GH + appetite stimulation	Long-term, clean GH support

Key takeaway: Hexarelin is the most powerful GHRP for raw GH output and the only one with CD36 cardioprotective effects. However, it requires the most careful management due to desensitization, cortisol, and prolactin. Choose Hexarelin for short, intense GH cycles; choose Ipamorelin for long-term, year-round use with minimal side effects.

Calculate Your Hexarelin Dose

Hexarelin is supplied as a lyophilized (freeze-dried) powder, typically in 2 mg or 5 mg vials. You reconstitute it with bacteriostatic water, then draw your dose using an insulin syringe. The concentration depends on how much water you add to the vial.

Worked Example:

Vial size: 5 mg (5,000 mcg) of Hexarelin
Bacteriostatic water added: 2.5 mL
Concentration: 5,000 mcg ÷ 2.5 mL = 2,000 mcg per mL
Target dose: 200 mcg
Volume to draw: 200 ÷ 2,000 = 0.1 mL = 10 units on an insulin syringe

Quick Reference — 5 mg Vial

Bac Water Added	Concentration	100 mcg Dose	200 mcg Dose
1 mL	5,000 mcg/mL	2 units (0.02 mL)	4 units (0.04 mL)
2 mL	2,500 mcg/mL	4 units (0.04 mL)	8 units (0.08 mL)
2.5 mL	2,000 mcg/mL	5 units (0.05 mL)	10 units (0.1 mL)
5 mL	1,000 mcg/mL	10 units (0.1 mL)	20 units (0.2 mL)

Skip the Math — Use Our

Enter your vial size, water volume, and desired dose — get instant calculations with zero manual math.

Hexarelin Dosage by Goal

Hexarelin's dual mechanism (GH release + CD36 cardioprotection) makes it applicable to multiple goals. The optimal protocol varies depending on whether you are targeting maximum GH output, body composition, cardiac benefits, or general recovery.

Maximum GH Release & Muscle Growth

For users seeking the largest possible GH pulse to support muscle protein synthesis, recovery, and anabolic signaling. Best combined with a GHRH analog for synergistic output. This is the most aggressive protocol and carries the highest desensitization risk.

Dose: 200 mcg per injection (SubQ)
Frequency: 2–3x daily, all fasted
Cycle: 4–6 weeks on, 4–6 weeks off (mandatory)
Stack: + CJC-1295 (no-DAC) 100 mcg at each injection for 3–5x synergistic GH output

Fat Loss & Body Recomposition

GH elevation promotes lipolysis (fat breakdown) and improves body composition over time. Hexarelin's potent GH pulse makes it effective for fat loss protocols, though results develop over weeks. Moderate dosing reduces side effects while maintaining meaningful GH elevation.

Dose: 100–200 mcg per injection (SubQ)
Frequency: 2x daily (morning fasted + before bed fasted)
Cycle: 6–8 weeks on, 6–8 weeks off
Note: The before-bed injection synergizes with the natural nocturnal GH pulse for enhanced overnight fat oxidation

Cardioprotection (CD36 Pathway)

For users primarily interested in Hexarelin's unique CD36-mediated cardiac benefits — reduced fibrosis, ischemia-reperfusion protection, and improved LVEF. The CD36 effect occurs at standard doses and does not require maximum GH protocols. A lower, more sustainable approach is appropriate.

Dose: 100–200 mcg per injection (SubQ)
Frequency: 1–2x daily
Cycle: 4–8 weeks on, equal time off
Note: CD36 binding occurs at standard dosing; no need to push to maximum GH doses for cardiac benefit

CD36 is unique to Hexarelin. If cardiac support is your primary goal, Hexarelin is the only GHRP that provides it. Ipamorelin, GHRP-2, and GHRP-6 do not bind CD36 and have no demonstrated cardioprotective effects beyond general GH-mediated benefits.

Recovery & Anti-Aging

Conservative dosing for users seeking improved sleep quality, faster recovery from training, skin quality, and general anti-aging benefits associated with optimized GH levels. Lower doses reduce desensitization risk and side effects.

Dose: 100 mcg per injection (SubQ)
Frequency: 1–2x daily (before bed is ideal)
Cycle: 4–8 weeks on, equal time off
Alternative: Consider Ipamorelin for year-round use if desensitization management is a concern

Consistency and cycling matter more than dose size. A moderate dose taken consistently on a proper cycle will outperform aggressive dosing that leads to desensitization. Choose a sustainable protocol you can maintain for the full cycle duration.

Desensitization Management

Desensitization is the single most important consideration when using Hexarelin. Continuous daily stimulation of the GHS-R1a receptor causes progressive downregulation, reducing the GH pulse over time. This is not a minor concern — it is the primary limitation of Hexarelin and the reason it must be cycled.

Cycling is mandatory, not optional. Unlike Ipamorelin (which can be used long-term with minimal desensitization), Hexarelin requires structured on/off cycling. Failing to cycle is the single most common mistake with this peptide.

Cycling Protocols

Protocol	On-Cycle	Off-Cycle	Notes
Conservative	4 weeks	4 weeks off	Lowest desensitization risk; best for first-time users
Standard	6 weeks	6 weeks off	Most common protocol; balances effectiveness with receptor recovery
Maximum	8 weeks	8 weeks off	Upper limit; some GH blunting may occur in weeks 6–8
Rotation Strategy	4–6 weeks Hexarelin	4–6 weeks Ipamorelin	Year-round GH support; Ipamorelin during off-cycle maintains GH without further desensitization

The Hexarelin-to-Ipamorelin Rotation

The most popular year-round strategy for GHRP users who want sustained GH support. Run Hexarelin for 4–6 weeks for maximum GH potency and CD36 cardioprotection, then switch to Ipamorelin for 4–6 weeks while GHS-R1a receptors recover. Ipamorelin's minimal desensitization risk makes it safe for the off-cycle period. This rotation provides continuous GH elevation without the receptor downregulation that would occur with non-stop Hexarelin use.

Signs of Desensitization

Reduced GH-related effects compared to the first weeks of the cycle (less pronounced sleep improvement, recovery, or body composition changes)
Diminishing “flush” or warmth sensation post-injection (if previously experienced)
Reduced appetite response compared to early in the cycle
If IGF-1 blood work is available: declining IGF-1 levels despite consistent dosing

If you suspect desensitization has occurred: End the cycle early and begin the off-period. Do not try to “push through” by increasing the dose — this accelerates receptor downregulation and is counterproductive. Allow a full off-cycle (at minimum 4 weeks) before restarting Hexarelin.

Hexarelin Stacking Protocols

Hexarelin stacking follows one fundamental rule: pair with a GHRH analog, never with another GHRP. GHRPs and GHRHs work through different mechanisms that synergize powerfully, while stacking multiple GHRPs is redundant (they compete for the same receptor) and accelerates desensitization.

Hexarelin + CJC-1295 — The Gold Standard (GHRP + GHRH Synergy)

The most effective Hexarelin stack. Hexarelin triggers the GH pulse via GHS-R1a, while CJC-1295 (a GHRH analog) amplifies and sustains it via the GHRH receptor. Together they produce 3–5 times the GH output of either peptide alone. This is the single most impactful addition to any Hexarelin protocol.

Compound	Dose	Frequency	Purpose
Hexarelin	100–200 mcg SubQ	2–3x daily (fasted)	GH pulse trigger (GHS-R1a) + CD36 cardioprotection
CJC-1295 (no-DAC)	100 mcg SubQ	At each Hexarelin injection	Amplifies and sustains the GH pulse (GHRH receptor)

Protocol note: Use CJC-1295 no-DAC (also called Mod GRF 1-29) for pulsatile protocols where you inject multiple times daily. CJC-1295 with DAC provides sustained baseline GH elevation over days and is dosed less frequently (1–2x per week at 1–2 mg). Both work synergistically with Hexarelin — the choice depends on whether you prefer pulsatile or sustained GH elevation.

Hexarelin + BPC-157 (GH Pulse + Targeted Tissue Repair)

Combines Hexarelin's systemic GH elevation with BPC-157's localized tissue repair for injury recovery protocols. Hexarelin supports recovery through elevated GH and IGF-1, while BPC-157 provides direct angiogenesis and growth factor upregulation at the injury site.

Compound	Dose	Frequency	Purpose
Hexarelin	100–200 mcg SubQ	1–2x daily (fasted)	Systemic GH elevation, IGF-1, recovery support
BPC-157	250 mcg SubQ	1–2x daily (near injury)	Localized tissue repair, angiogenesis, growth factor upregulation

Hexarelin → Ipamorelin Rotation (Year-Round GH Strategy)

The most practical approach for sustained GH support across the calendar year. Alternate between Hexarelin (maximum potency, CD36 benefits) and Ipamorelin (clean profile, no desensitization) in equal-length cycles. This provides continuous GH elevation without the receptor downregulation that would occur with non-stop Hexarelin.

Phase	Compound	Dose	Duration
On-Cycle	Hexarelin (+ CJC-1295 optional)	100–200 mcg, 2–3x daily	4–6 weeks
Off-Cycle	Ipamorelin (+ CJC-1295 optional)	200–300 mcg, 1–3x daily	4–6 weeks

Hexarelin + Sermorelin (GHRP + Natural GHRH)

An alternative to CJC-1295 for users who prefer a more natural GHRH analog. Sermorelin is a 29-amino-acid GHRH analog that stimulates pituitary GH release through the GHRH receptor, synergizing with Hexarelin's GHS-R1a mechanism. Sermorelin has a shorter half-life than CJC-1295 and produces a more physiological GH pattern.

Compound	Dose	Frequency	Purpose
Hexarelin	100–200 mcg SubQ	1–2x daily (fasted)	GH pulse trigger + CD36 cardioprotection
Sermorelin	200–300 mcg SubQ	At each Hexarelin injection	GHRH receptor agonist; amplifies GH pulse naturally

Do NOT stack Hexarelin with other GHRPs. Combining Hexarelin with GHRP-2, GHRP-6, or Ipamorelin simultaneously is redundant — they all compete for the same GHS-R1a receptor. This does not produce additive GH release and accelerates desensitization. Instead, rotate between GHRPs and stack with a GHRH analog (CJC-1295 or Sermorelin) for true synergy.

Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.

Safety, Side Effects & Contraindications

Safety Profile: Hexarelin is the most potent GHRP, which means it has the strongest side effect profile of the GHRP family. Cortisol and prolactin elevation are more pronounced than with GHRP-2, GHRP-6, or Ipamorelin. Desensitization is the primary safety concern. Clinical studies have shown it to be generally well-tolerated at standard doses when properly cycled, but long-term human safety data is limited.

Common Side Effects

Dose-dependent and generally manageable:

Cortisol elevation — more pronounced than other GHRPs; may affect sleep, mood, or body fat distribution at higher doses
Prolactin elevation — may cause breast tenderness, low libido, or mood changes in sensitive individuals
Moderate appetite increase — less intense than GHRP-6 but more than Ipamorelin
Water retention and bloating — common with GH elevation, usually mild and transient
Injection site redness, soreness, or minor swelling
Numbness or tingling in extremities — related to GH effects on fluid balance

Less common:

Headache — usually in the first few days, resolves with continued use
Flushing or warmth sensation post-injection — generally harmless
Fatigue or lethargy — may indicate cortisol dysregulation at high doses

Desensitization is the primary concern — not acute side effects. Hexarelin's side effects are manageable with proper dosing and cycling. The real risk is losing GH response from continuous use. Cycle properly (4–8 weeks on, equal time off) and do not exceed 200 mcg per injection.

Contraindications

Active cancer or history of cancer — GH elevation promotes cell proliferation. Elevated GH and IGF-1 could theoretically support tumor growth. Avoid use with active malignancies.
Pregnancy and breastfeeding — no safety data exists for Hexarelin during pregnancy or nursing. Avoid entirely.
Pituitary disorders — Hexarelin acts directly on pituitary somatotrophs. Pre-existing pituitary tumors or dysfunction are contraindications.
Uncontrolled diabetes — GH elevation can worsen insulin resistance and blood glucose control. Use with medical supervision only in diabetic patients.
Hyperprolactinemia — Hexarelin elevates prolactin more than other GHRPs. Pre-existing elevated prolactin is a contraindication.

When to Stop or Reduce Dose

Signs of elevated prolactin (breast tenderness, gynecomastia, low libido, menstrual irregularity)
Signs of elevated cortisol (disrupted sleep, increased anxiety, unexplained weight gain, especially abdominal)
Significant water retention or persistent bloating that does not resolve
Suspected desensitization (diminishing effects despite consistent dosing) — end the cycle early
Any symptom that feels unusual or concerning — err on the side of caution

Regulatory Status: Hexarelin is not FDA-approved for human use. It is classified as a research peptide / research chemical. It is prohibited by WADA (World Anti-Doping Agency) for competitive athletes. Regulations vary by jurisdiction — verify your local laws before purchasing.

Common Hexarelin Dosing Mistakes

Avoid these common errors to get the most out of your Hexarelin protocol:

Not cycling Hexarelin (the single biggest mistake): Hexarelin has the highest desensitization risk of any GHRP. Continuous daily use beyond 8 weeks dramatically blunts the GH response. You must cycle 4–8 weeks on, equal time off. This is not optional — it is mandatory for Hexarelin to remain effective.

Injecting in a fed state: Food, especially fats and carbohydrates, blunts the GH response by elevating blood glucose and free fatty acids. Always inject fasted — at least 2 hours after eating, 30–45 minutes before eating. This applies to every injection.

Exceeding 200 mcg per injection: Research shows a clear dose-response ceiling at 200 mcg. Doses above this do not produce proportionally greater GH release but do increase cortisol, prolactin, and side effects. More is not better with Hexarelin.

Stacking Hexarelin with other GHRPs: GHRPs compete for the same GHS-R1a receptor. Stacking Hexarelin with GHRP-2, GHRP-6, or Ipamorelin simultaneously is redundant and accelerates desensitization. Instead, stack with a GHRH analog (CJC-1295) and rotate between GHRPs during off-cycles.

Injecting doses too close together: Space injections at least 3 hours apart to allow the pituitary to replenish GH stores. Injecting 2x or 3x daily with less than 3 hours between doses wastes peptide — the second pulse will be significantly blunted.

Ignoring cortisol and prolactin symptoms: Hexarelin elevates both cortisol and prolactin more than other GHRPs. Watch for signs of elevated cortisol (disrupted sleep, increased belly fat, anxiety) and elevated prolactin (breast tenderness, low libido, mood changes). If symptoms appear, reduce dose or shorten the cycle.

Using the same GHRP during on and off cycles: When you cycle off Hexarelin, do not simply switch to continuous Hexarelin at a lower dose. The off-cycle is meant to restore GHS-R1a receptor sensitivity. Use Ipamorelin during off-periods if you want continued GH support, as it has minimal desensitization risk.

Not pairing with a GHRH analog: Hexarelin alone produces a strong GH pulse, but combining it with CJC-1295 produces 3–5x greater output through synergistic mechanisms. Using Hexarelin without a GHRH is leaving significant GH potential on the table.

Expecting immediate visible results: GH-mediated effects (improved body composition, recovery, sleep quality) develop over weeks, not days. Most users notice sleep improvements within 1–2 weeks and body composition changes at 4–6 weeks. Stick with the full cycle before evaluating results.

Frequently Asked Questions

Key Takeaways

Hexarelin is the most potent GHRP — it produces the largest GH pulse of any growth hormone releasing peptide
Standard dose: 100–200 mcg SubQ, 1–3x daily fasted — do not exceed 200 mcg per injection (dose-response ceiling)
Unique CD36 cardioprotection — Hexarelin is the only GHRP that binds CD36 scavenger receptors, reducing cardiac fibrosis and protecting against ischemia-reperfusion injury
Cycling is mandatory: 4–8 weeks on, equal time off. Hexarelin has the highest desensitization risk of any GHRP
Gold standard stack: Hexarelin + CJC-1295 for 3–5x synergistic GH output through complementary GHRP + GHRH mechanisms
Never stack with other GHRPs — they compete for the same receptor. Rotate between GHRPs instead (Hexarelin on-cycle, Ipamorelin off-cycle)
Cortisol and prolactin elevation are more pronounced than with other GHRPs — monitor for symptoms and reduce dose if needed
Always inject fasted — food blunts the GH response. Wait at least 2 hours after eating and 30–45 minutes before eating
Space injections 3+ hours apart to allow pituitary GH stores to replenish between pulses
Not FDA-approved — classified as a research peptide. Banned by WADA for competitive athletes. Check local regulations.

This article is for educational and informational purposes only. See our Disclaimer.

References

Arvat E, et al. “Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.” J Clin Endocrinol Metab. 2001;86(3):1169-1174. PubMed
Broglio F, et al. “Endocrine and non-endocrine actions of ghrelin.” Horm Res. 2003;59(3):109-117. PubMed
Muccioli G, et al. “Growth hormone-releasing peptides and the cardiovascular system.” Ann Endocrinol (Paris). 2000;61(1):27-31. PubMed
Ghigo E, et al. “Growth hormone-releasing peptide-6 and hexarelin as diagnostic and therapeutic agents.” Horm Res. 1999;51 Suppl 3:59-63.
Rahim A, et al. “Acute administration of hexarelin, a synthetic growth-hormone-releasing peptide, in healthy elderly subjects.” Clin Endocrinol (Oxf). 1998;49(4):487-492.
Mao Y, et al. “Hexarelin treatment preserves myocardial function and reduces cardiac fibrogenesis in diabetic rats.” Mol Cell Endocrinol. 2014;382(1):264-274.
Locatelli V, et al. “Growth hormone-releasing peptides and their analogs.” Front Neuroendocrinol. 1999;20(1):47-72.
Muccioli G, et al. “Hexarelin binds to cardiac and skeletal muscle receptors.” Endocrinology. 1998;139(9):4093-4097.
Arvat E, et al. “Preliminary evidence for an anti-aging effect of hexarelin in elderly subjects.” Growth Horm IGF Res. 1998;8 Suppl B:77-81.

Next Steps

Continue your research with these resources.

Ipamorelin Dosage Guide

Learn dosing protocols for Ipamorelin — the ideal off-cycle GHRP for year-round rotation with Hexarelin.

Read Guide

Dosage Calculator

Calculate your exact Hexarelin dose based on vial size and reconstitution volume.

Open Calculator

Peptide Directory

Browse all peptides with research summaries and dosing data.

View Directory